A Scalable Formulation for Engineering Combination Therapies for Evolutionary Dynamics of Disease

Vanessa Jonsson, Anders Rantzer and Richard M. Murray

Abstract—It has been shown that optimal controller synthesis for positive systems can be formulated as a linear program. Leveraging these results, we propose a scalable iterative algorithm for the systematic design of sparse, small gain feedback strategies that stabilize the evolutionary dynamics of a generic disease model. We achieve the desired feedback structure by augmenting the optimization problems with $\ell_1$ and $\ell_2$ regularization terms, and illustrate our method on an example inspired by an experimental study aimed at finding appropriate HIV neutralizing antibody therapy combinations in the presence of escape mutants.

I. INTRODUCTION AND MOTIVATION

A challenge inherent to the treatment of certain infectious and non-infectious diseases, such as HIV or cancer, is the risk that the pathogen or tumor will evolve away and become resistant to treatment methods that comprise the standard of care. Especially vulnerable to this phenomenon are treatment methods that involve exposing the disease population (such as viruses or cancer cells) to therapies targeting specific molecules involved in disease progression for an extended period of time. While these targeted therapies have the benefit of allowing physicians to tailor treatments to a patient’s tumor cell population, they nonetheless establish an environment in which the occurrence of mildly drug resistant pathogens or tumor cells can develop an evolutionary advantage over those for which the therapy is targeted, leading to so called ‘treatment-escape’.

One of the solutions that has been proposed [1], [2] is the rational design of combination therapy, an approach that requires the identification of targets that are known to play a key role in disease progression. An example of a multi target therapy currently used for the treatment of chronic HIV infection is highly active antiretroviral therapy (HAART), which is comprised of a combination of antiretroviral drugs that target specific enzymes involved during different points of the infection cycle.

Recent results by Rosenbloom, et al. [1] have been more quantitative in nature, modeling the evolutionary dynamics of HIV and showing through simulations how the effect of antiretroviral dynamics can determine HIV evolution and therapy outcome. The Michor lab [2] recently showed the effects of different erlotinib dosing strategies in the presence of pharmacokinetic fluctuations on the evolution of resistance of non small cell lung cancer through simulations of a stochastic evolutionary dynamics model.

Although these methods have provided some insight into the problem, the challenge of designing treatment protocols that prevent escape is one that has been more recently addressed by control theoretic methods. For cancer therapy, results in this spirit apply methods from optimal and receding horizon control [3], [4], as well as gain scheduling [5], to synthesize treatment protocols that are robust to parameter uncertainty, an inherent issue in all biological systems. In the context of HIV and antiretroviral therapy, the authors in [6] propose a discrete time formulation that allows for the design of switching therapy strategies to delay the emergence of highly resistant mutant viruses.

In [7], we introduced a general algorithm that used an $H_\infty$ approach for the principled design of targeted combination therapy concentrations that explicitly account for the evolutionary dynamics of a generic disease model. This algorithm was effective in generating robustly stabilizing controllers, however it suffered from an inherent lack of scalability symptomatic of semidefinite programming formulations. Here, we propose a scalable solution to the combination therapy problem by reformulating it as a second order cone program (SOCP).

We also address the requirement that the synthesized controller be not only robust to unmodeled dynamics but also exhibit sparse structure and small feedback gains. This is motivated by the fact that the number of therapies commonly used in combination to treat a disease is often small while the number of potential usable therapies are often very large [8]. Targeted therapies such as small molecule drugs or antibodies exhibit a maximum effective concentration beyond which side effects are likely to worsen and no additional drug benefits are seen.

In particular, through $\ell_1$ and $\ell_2$ regularization, we induce sparse structure in the feedback controller while bounding the magnitude of the feedback gains. This leads to a SOCP formulation of the combination therapy synthesis problem. The main contribution of this paper is a scalable algorithm for the systematic design of sparse, small gain feedback strategies to stabilize the evolutionary dynamics of a generic disease model.

The article is structured as follows: In Section II, we recall the extended quasispecies evolutionary dynamics model that encodes replication, mutation and neutralization and summarize relevant results in controller design of positive systems. In Section III, we present our $L_1$ combination therapy synthesis algorithm. Section IV illustrates our al-
algorithm in the context of an HIV antibody therapy design problem previously studied in an experimental setting [9]. In this section we also compare performance and scalability properties of our $L_1$ algorithm and the previously developed $H_{\infty}$ algorithm [7]. Section V ends with concluding remarks and directions for future work.

II. PRELIMINARIES

A. Notation

$\mathbb{R}_+$ denotes the set of nonnegative real numbers. The inequality $X > 0, (X \geq 0)$ means that all elements of the matrix or vector X are positive (nonnegative). $X > 0$ means that X is a symmetric and positive definite matrix. The matrix $A \in \mathbb{R}^{n \times n}$ is said to be Hurwitz if all eigenvalues have negative real part. Finally, the matrix is said to be Metzler if all off-diagonal elements are nonnegative. Define $1_n$ to be the vector of all ones of dimension n. The induced matrix norm for a matrix $M \in \mathbb{R}^{r \times m}$ is

$$\|M\|_{p-\text{ind}} = \sup_{w \in \mathbb{R}^m} \frac{|Mw|_p}{|w|_p}$$

where $|w|_p = (\sum_{i=1}^{n} w_i^p)^{1/p}$, and $G(s) = C(sI - A)^{-1}B + D$ be a $r \times m$ matrix transfer function. The induced norms of the corresponding impulse response $g(t) = Ce^{At}B + D\delta(t)$ are

$$\|g\|_{p-\text{ind}} = \sup_{w \in \mathbb{L}_p^r} \frac{\|g * w\|_p}{\|w\|_p}$$

for $w \in \mathbb{L}_p^r$, given that $g * w \in \mathbb{L}_p^r$ is the convolution of $g$ and $w$. Finally we refer to the $\infty$-induced robust controller as the $L_1$ controller as is customary in the robust control literature.

B. Problem formulation

The quasispecies model [10] was originally developed to describe the dynamics of populations of self replicating macromolecules undergoing mutation and selection. We choose this model for its relative simplicity and its ability to capture the salient features of the evolutionary dynamics of a simplified generic disease model. In [7] we incorporated the effects of potential therapies into the basic quasispecies model, by defining a drug binding reaction, $\ell \cdot x \rightarrow K_\ell \cdot x$ — drug $\ell$ binds to self replicating macromolecule $x$ with association rate $K_\ell$, giving a neutralized complex $\ell \cdot x$. The extended quasispecies model for n mutants and m drugs, is written as:

$$\dot{x}_i = (r_i q_{ii} - d_i) x_i + \sum_{k \neq i} r_i q_{ik} x_k - \sum_{k=1}^{m} \psi_{ki} \ell_k x_i$$  \hspace{1cm} (1)$$

where $x_i \in \mathbb{R}_+$ is the concentration of mutant $i$, $\ell_k \in \mathbb{R}_+$ is the drug concentration (assumed to remain at constant concentrations throughout), $r_i$ and $d_i$ are the replication and degradation rates, respectively, of mutant $i$, and $q_{ik}$ is the probability that mutant $k$ mutates to mutant $i$. Finally, $\psi_{ki} = f(K_{ki})$ is a function of the association constant $K_{ki}$ for each neutralization reaction representing the rate at which a neutralizing macromolecule $\ell_k$ neutralizes mutant $i$. The rates $r_i$ and $\psi_{ki}$ can be viewed as replication and neutralization fitnesses of mutant $i$. When $\ell_k = 0, \forall k \in \{1, ..., m\}$, the quasispecies dynamics are unstable.

The following state space representation of equation (1) emphasizes the inherent feedback structure that arises from drug binding reactions:

$$\dot{x} = (A - \Psi L)x + w$$

$$z = Cx$$

with (i) $A \in \mathbb{R}^{n \times n}$, with $A_{ij} = r_i q_{ij} \geq 0 \ \forall \ i \neq j$ and $A_{ii} = r_i q_{ii} - d_i$, that encodes the mutation and replication dynamics; (ii) $\Psi \in \mathbb{R}^{n \times m}$ a block diagonal matrix that describes the fitness of n mutants with respect to m different drugs, with diagonal elements $\Psi_i = (\psi_{ki}) \in \mathbb{R}^{1 \times m}$; (iii) $L = (I \otimes \ell) \in \mathbb{R}^{n \times n}$, with $\ell = (\ell_k) \in \mathbb{R}^m$, a block diagonal matrix that encodes the concentrations of drugs for all n mutants; (iv) $C = [1_n \ L^T]^T \in \mathbb{R}^{(mn+1) \times n}$, and (v) $w \in \mathbb{R}^n$, an arbitrary positive disturbance. Note that $\Psi L \in \mathbb{R}_+^{n \times n}$ is by construction a diagonal matrix.

We set the regulated output $z = [z_1 \ z_2]^T = Cx$ where $z_1 = x_1 + \cdots + x_n$ minimizes the total virus population and $z_2 = Lx$ serves as a proxy to minimizing the concentration of drugs needed to robustly stabilize the system.

Remark I: A is a Metzler matrix with off-diagonal entries that are several orders of magnitude smaller than the diagonal entries. This is due to the biological fact that mutation rates range from $10^{-5} - 10^{-9}$ mutations per base pair per replication cycle for reverse transcriptase to DNA replication. Letting $G$ denote the closed loop system (2), the control task then becomes to design drug concentrations $\ell$ by finding a controller $L = (I \otimes \ell)$ that leads to a stable $G$ satisfying $||G||_{\infty-\text{ind}} < \gamma$, for some robustness level $\gamma > 0$.

C. Linear programming controller synthesis for positive systems

Our previous work [7] provided a semi definite program (SDP) formulation to synthesize $H_{\infty}$ controllers that stabilize the evolutionary dynamics of a generic disease model as described by the extended quasispecies model. One feature of our system was its internal positivity, which allowed us to restrict the storage function matrix used in the bounded real lemma to be strictly diagonal [11] [12]. Although this reduced the number of decision variables in the SDP, it was not enough to offset the inherent lack of scalability of semidefinite programming. Scalability is an important consideration when designing combination therapies where the number of possible mutants can be large, such as for the treatment of chronic HIV infection. Recent results [12],[13] on the synthesis of controllers for positive systems show that the design of structured static state feedback controllers for internally positive systems can be reformulated as a convex problem with methods that scale linearly with the number of non zero elements in the feedback matrix. In this section we provide a brief survey of the relevant definitions and results from [13]:

Theorem I: For the system:


\[
\begin{align*}
\dot{x} &= (A + ELF)x + Bw \\
z &= (C + GLF)x + Dw
\end{align*}
\]  

(3)

let \(D\) be the set of \(m \times m\) diagonal matrices with entries in [0,1]. Suppose that \(A + ELF\) is Metzler and \(C + GLF \geq 0\) for all \(L \in D\). Let \(g(t)\) be the impulse response of \(G(s) = (C + GLF)[sI - (A + ELF)]^{-1}B + D\) 

If the matrices \(B, D\) and \(F\) have non-negative coefficients, then the following two conditions are equivalent:

1. There exists an \(L \in D\) with \(A + ELF\) Hurwitz and \(\|g\|_{\infty} \leq \gamma\).
2. There exists a \(\xi, \mu \in \mathbb{R}^m_+\) such that

\[
\begin{align*}
A\xi + E\mu + B1 &< 0 \\
C\xi + G\mu + D1 &< \gamma1 \\
\mu &\leq F\xi
\end{align*}
\]

If \(\xi, \mu\) satisfy the linear constraints 2) then the stability and norm guarantees of 1) hold for every \(L\) such that \(\mu = LF\xi\).

Input-output performance is characterized using induced norms which are determined by the closed loop system’s static gain:

**Theorem 2:** For an \(r \times m\) transfer matrix \(G(s) = C(sI - A)^{-1}B + D\), let \(g(t) = Ce^{At}B + D\delta(t)\) be the corresponding impulse response, where \(Ce^{At}B \geq 0\) for \(t \geq 0\) and \(D \geq 0\), with \(A\) Hurwitz. Then \(\|g\|_{p-\text{ind}} = \|G(0)\|_{p-\text{ind}}\) for \(p = 1\), \(p = 2\) and \(p = \infty\).

The positive nature of the system allows us to restrict ourselves to linear storage functions, which in turn allows for sparse structure to be imposed on the feedback gain [12]. Our feedback gain \(L = I \otimes \ell\) is not only structurally constrained to be block diagonal, but algebraically constrained as well, in that all block diagonal components must be equal. Unfortunately, there is no known convex reformulation for this additional constraint.

### D. Regularization for structured controller synthesis

The biomedical justification for wanting a simple controller structure with small gains is twofold: first, the number of therapies that can be used simultaneously to treat a disease is often limited, and second to minimize side effects, it is desirable to keep the magnitude of drug concentrations small while being robust to evolution. These design specifications can be expressed with the use of regularization, a common technique used in machine learning and inverse problems for model identification [14], [15], [16], [17] and increasingly used for controller design [18], [19], [20], [21]. As such, we introduce \(\ell_1\) and \(\ell_2\) penalties in our design objective to promote controller sparsity and minimize controller gains.

We combine these regularization techniques with controller synthesis results for positive systems and present an iterative algorithm that yields a suboptimal \(L_1\) controller. This formulation of the combination therapy problem allows the designer to explore explicit trade-offs between closed loop performance, sparsity in controller structure and gain minimization.

### III. A Sub-optimal \(L_1\) Combination Therapy Controller

In this section, we address the aforementioned non-convexity of the optimal control problem by formulating an iterative algorithm for finding effective drug concentrations. Our main result addresses the issue of synthesizing a stabilizing controller subject to the constraints imposed by the quasispecies model (2), with acceptable robustness properties characterized in terms of its \(\infty\)-induced closed loop norm.

#### A. Initializing stabilizing controller

We begin by synthesizing a stabilizing controller to use as an initial controller in our iterative algorithm, as noted in Remark 5. We recall a simple algorithm developed in [7] for the synthesis of a stabilizing controller, which admits a particularly simple formulation in light of the Metzler nature of \(A\) and the diagonal structure of \(\Psi L\).

**Lemma 1:** There exists \(\epsilon > 0\) such that the solution to the convex program:

\[
\begin{align*}
\text{minimize} & \quad ||\ell||_\infty \\
\text{subject to} & \quad A_d + \epsilon I - \Psi L < 0 \\
& \quad L = I \otimes \ell
\end{align*}
\]

is a stabilizing controller for system (2), where \(A_d \in \mathbb{R}^{n \times n}_+\) is a diagonal matrix such that \((A_d)_{ii} = (A)_{ii}\) where \(A\) is the replication and mutation matrix in equation (2).

**Remark 2:** The resulting LMI is strictly diagonal, and so reduces to an LP.

**Proof:** Rewrite \(A = A_d + M\) where \(A_d\) is diagonal and \(M = \{m_{ij}\} \in \mathbb{R}^{n \times n}\), \(m_{ij} = 0\) for \(i = j\) and \(m_{ij} > 0\) for \(i \neq j\). By the Perron Frobenius theorem, there exists \(r > 0\) such that the spectral radius \(\rho(M) = r \leq \max_{i} \sum_{j} m_{ij}\). Let \(\epsilon = \max_{i} \sum_{j} m_{ij}\) and rewrite \(M = \epsilon I - (\epsilon I - M) - \Psi L < A_d + \epsilon I - \Psi L < 0\), yielding the desired stability. \(\blacksquare\)

#### B. A Suboptimal \(L_1\) combination therapy controller

Observe that through a straightforward application of Theorem 2, with \(B = I\), \(C = [I_n \ L^T]^T\), \(D = 0\), \(E = -\Psi\), \(F = I\) to system (1), solving the following non-convex program:

\[
\begin{align*}
\text{minimize} & \quad ||Cx||_\infty + \lambda_1 ||\ell||_1 + \lambda_2 ||\ell||_2 \\
\text{subject to} & \quad Ax + Kx + 1 \leq 0 \\
& \quad K = \Psi L \\
& \quad L = I \otimes \ell \\
& \quad x \geq 0
\end{align*}
\]

(5)
will yield a sparse combination of drug concentrations $\ell$, yielding an optimal $\infty$-induced closed loop norm for appropriately chosen regularizers $\lambda_1 \geq 0, \lambda_2 \geq 0 \in \mathbb{R}$.

Remark 3: We can impose an additional constraint limiting the concentrations of candidate therapies. This is necessary with certain drugs that have maximum tolerated doses dictated by clinical trials.

As mentioned earlier, there are no known convex reformulations of this problem due to the additional structure on $L$. As such, we suggest the following iterative algorithm, based on the convex programs (6) and (7), to find a stabilizing controller. For notation, let $Y = P_Z(x, \gamma)$ denote an optimization problem $P$ in which we optimize over $x$ and $\gamma$ leaving $Z$ fixed and with solution $Y$.

**Program 1.** $P_1(\ell, \gamma)$:

$$\begin{align*}
\text{minimize} & \quad \gamma, \ell \in \mathbb{R}^L_2 \\
\text{subject to} & \quad Ax + \Psi Lx + 1 \leq 0 \\
& \quad L = I \otimes \ell, \ C = [1_n \ LT]^T \\
& \quad x \geq 0 \\
& \quad \gamma \geq ||Cx||_{\infty}
\end{align*}$$

**Program 2.** $P_2(\ell, \gamma)$:

$$\begin{align*}
\text{minimize} & \quad \gamma + \lambda_1 ||\ell||_1 + \lambda_2 ||\ell||_2 \\
\text{subject to} & \quad Ax + \Psi Lx + 1 < 0 \\
& \quad L = I \otimes \ell, \ C = [1_n \ LT]^T \\
& \quad \gamma \geq ||Cx||_{\infty}
\end{align*}$$

We now present our algorithm:

**Algorithm 1 Scalable Combination Therapy**

1) Set $\epsilon > 0$.
2) **Solve for initial stabilizing controller $\ell^0$:**
   
   Solve (4) to obtain controller $\ell^0$.
   
   Set $(x^0, \gamma) = P_1(\ell^0, x, \gamma)$.
   
   Set $(\ell^0, \gamma) = P_2(x^0, \ell^0(\ell, \gamma)$.
3) **Find $(\lambda_1, \lambda_2, \ell) that minimize $\gamma$:**

   $$\forall (\lambda_1, \lambda_2) \in \Lambda_1 \times \Lambda_2, \lambda_1, \lambda_2 \in \mathbb{R}_+^L,$$

   while $\gamma - \gamma > \epsilon$

   Set $(x, \gamma) = P_1(\ell, x, \gamma)$.

   Set $(\ell, \gamma) = P_2(\ell, \gamma)$.

   Set $\gamma = \gamma$.

**Remark 4:** The sequence of $\gamma$’s defined by the iterative process in Algorithm 1 is non increasing by construction, and bounded below by 0, thus implying convergence. An initial stabilizing controller can always be found as shown in [7], and thus the algorithm can always be initialized. We therefore have that our algorithm always converges to a feasible, local minimum robustness value $\gamma$, generating a stabilizing controller for (2).

**Remark 5:** In practice, we note that the $L_1$ controller suffers from dependence on initial conditions and converges to local optima quickly, yielding a stabilizing controller with robustness properties that are not significantly different from the nominal controller. A solution to this is to iterate once through $P_1$ and $P_2$, with $\lambda_1 = \lambda_2 = 0$ and initialize the algorithm with the resulting controller.

**Remark 6:** Due to the presence of the $\ell_2$ regularizer, $P_2$ and (5) are SOCPs and not linear programs. As it will be clearly demonstrated in the example in the next section, this is still more efficient than the SDP combination therapy algorithm from [7]. In addition, the second order cone constraint is only on the drug concentrations so it should have minimal effect on performance, given that the number of antibodies is small compared to the number of mutants.

IV. HIV/ANTIBODY THERAPY APPLICATION

Our results provide a principled approach to the design of antibody treatments for chronic infection with human immunodeficiency virus-1 (HIV-1). We illustrate this with an example motivated by experimental results of evolutionary dynamics of HIV-1 in the presence of antibody therapy obtained in [9].

A relatively recent discovery is that a minority of HIV-infected individuals can produce broadly neutralizing antibodies (bNAb), that is, antibodies that inhibit infection by many strains of HIV [22]. These have been shown to inhibit infection by a broad range of viral isolates in vitro but also protect non-human primates against infection [22],[23], [24].

Recent experimental results conducted in the Nussenzweig lab at Rockefeller University have demonstrated that the use of single antibody treatments can exert selective pressure on the virus, but escape mutants due to a single point mutation can emerge within a short period of time [9]. Although antibody monotherapy did not prove effective, it was shown that equal, high concentrations of an antibody pentamix effectively control HIV infection and suppress viral load to levels below detection. The goal of this example is to demonstrate how our proposed algorithm offers a principled way to design combination antibody therapies that control HIV infection and prevent evolution of any set of known resistant mutants. In a realistic setting, the ability to do this relies on the knowledge of what resistant viruses may be selected for with single therapies, and so this algorithm would be most effective in conjunction with single antibody selection experiments.

1) **Model parameters:** We consider a system of eighteen to thirty five HIV mutants with five potential antibodies to use in combination. Figure 5 lists the mutants that evolved from monotherapy experiments with their corresponding half maximal inhibitory antibody concentration (IC50) in $\mu g/ml$, as measured by the Nussenzweig lab in [9]. Antibodies 3BC176, PG16, 45-46G54W, PGT128 and 10-1074 are potential combination therapy candidates.

Although virus replication rates can vary considerably depending on the nature of the mutations a virus may undergo, we choose replication rates to be $0.5 \text{ (ml·day)}^{-1}$ for all mutants. We justify this selection by noting that escape mutants grew to be dominant mutants during selection
experiments and assume that replication rate variability due to mutations were negligible.

The fitness function associated with the neutralization of a virus $i$ with respect to an antibody $j$ is a Hill function $\psi_{ij} = \frac{\ell_j^\gamma}{\ell_j^\gamma + K_{ij}^\gamma}$, where $n$ is the Hill coefficient, $\ell_j$ is the concentration of a given antibody $j$, and $K_{ij} = \frac{k_{on}}{k_{off}} = \frac{[x_i][\ell_j]}{[x_i][\ell_j]}$ is the association constant for the virus/antibody binding reaction. $\ell_j + x_i \rightarrow k_{on} \ell_j \cdot x_i$, and $k_{on}$ and $k_{off}$ are the on and off reaction rate constants. Note that the association constant represents the fraction bound of antibody/virus complexes in solution and that $K_{ij} = \frac{3\text{IC}50_i}{3\text{IC}50_j}$ is found by solving Equation (1) for one virus/antibody pair for the duration $[t_0, t_f] = [0, 3]$. We simplify the Hill function by setting the Hill coefficient $n = 1$, as there is evidence that that antibodies do not bind cooperatively. Our algorithm yields antibody concentrations near zero and this yields the linear approximation $\psi_{ij} = \frac{1}{K_{ij}}\ell_j$. In addition, the antibodies we consider in our example do not target the same epitope, in other words, do not bind competitively to the same sites on the virus, thereby reducing any coupling between antibody concentrations.

2) Mutation process: The mutation rate for HIV reverse transcriptase is $u = 3 \times 10^{-5}$ mutations/nucleotide base pair/replication cycle, and the HIV replication cycle is approximately 2.6 days. We approximate the rate of mutation for a particular amino acid mutation at a particular location to be $\frac{1}{n_a}u(1-u)^k = 1.443 \times 10^{-6}$ per replication cycle, where $k \approx 3000$ is the size of the genome in residues and $n_a = 19$ is the number of amino acids that can be mutated to. Our model supports forward point mutations and two point mutations. We do not consider back mutations, as the probability of mutation is negligible. Units of concentration in number of viruses/ml or number of antibodies/ml are used for states, and time is measured in days. The standard volume is $1 \text{ ml}$.

A. A comparison between $H_\infty$ and $L_1$ controllers

We seek to provide a qualitative comparison between controllers synthesized using the scalable $L_1$ and the $H_\infty$ algorithms. To do this, we adapt the formulation in [7] to include $\ell_1$ and $\ell_2$ regularization terms and solve the following non convex problem using our iterative algorithm.

\[
\begin{align*}
\text{minimize} & \gamma + \lambda_1\|\ell_1\|_1 + \lambda_2\|\ell_2\|_2 \\
\text{subject to} & \begin{bmatrix} A_{cl}^T X + X A_{cl} + C^T C & X \\
X & -\gamma I \end{bmatrix} < 0 \\
& A_{cl} = (A - \Psi L) \\
& C = [1^T L^T]^T \\
& L = I \otimes \ell \\
& X \succ 0, X \text{ diagonal}
\end{align*}
\]
not able to synthesize controllers using the $H_\infty$ algorithm for the full set of thirty five mutants from Figure 5.

B. $L_1$ controller synthesis, full HIV example

We synthesized a nominal stabilizing controller using (4) comprised of an antibody pentamix (0.4687, 0.7815, 0.6129, 0.6279, 0.8831) µg/ml of (3BC176, PG16, 45-46G54W, PGT128, 10-1074), and a robust controller using (8) that consisted of antibody trimix (0.6891, 0.6712, 1.0706) µg/ml of (3BC176, 4546-G54W, PGT128). These both were generated for the evolutionary dynamics of the full, thirty five HIV mutants listed in Figure 5.

Both antibody pentamix (stabilizing) and trimix (robustly stabilizing) controllers have similar gains and based on a cursory first glance, one might be tempted to believe these have comparable robustness properties. Indeed, for some simulations of the closed loop dynamics subjected to 5% random time invariant perturbations in plant dynamics, the nominal controller is stabilizing as seen in Figure 3. This is qualitatively consistent with the experimental results done in by the Nussenzweig lab in [9]. It was shown that with weekly injections of equal concentrations of the antibody pentamix holding concentrations constant, had viral loads that remained below the limit of detection during an entire treatment course in mice.

In [9] again, an antibody trimix of equal concentrations of 3BC176, PG16 and 45-46G54W was suggested and experimentally shown to produce a decline in the initial viral load. However, a majority of mice in the experimental study had a viral rebound to pre-treatment levels, suggesting that in these cases, the virus had evolved mutations that were resistant to the trimix treatment. To compare the performance of our $L_1$ synthesized controller with gains of (0.6891, 0.6712, 1.0706) µg/ml of (3BC176, 4546-G54W, PGT128) to the experimentally studied trimix, we chose equal concentrations of (3BC176, PG16, 45-46G54W), namely (1, 1, 1) µg/ml for the experimentally derived trimix. We found that even though total antibody concentrations were larger in our version of the experimental trimix, the robustly stabilizing controller synthesized by the $L_1$ algorithm nonetheless performed overall better; the closed loop norm were $\|G\|_\infty = 0.2941$ and $\|G\|_{\infty - \text{ind}} = 0.6533$ for the $L_1$ controller versus $\|G\|_\infty = 0.26433$ and $\|G\|_{\infty - \text{ind}} = 0.74572$ for the experimental trimix.

These simulations demonstrate that although many stabilizing solutions to the combination therapy problem exist, the best ones are found when design parameters such as a sparsity, limits on the magnitude of gains, and robustness guarantees are simultaneously considered. Experimentally searching for these combinations is infeasible as the number of potential therapies and possible concentrations to consider is experimentally intractable. We propose to guide these experimental activities with our ability to design and synthesize combination therapy controllers. As such, one could generate a family of controllers based on “design specifications” tailored not only the (viral or cellular) composition of the disease, but to explore tradeoffs between number of therapies used (sparsity), therapy concentrations (magnitude of the gain) and ability to support pharmacokinetic fluctuations (robustness to perturbations) and subsequently verify these experimentally.

V. CONCLUSION AND FUTURE WORK

Leveraging recent results in positive systems, we proposed a scalable SOCP based iterative algorithm for the systematic design of sparse, small gain feedback strategies that stabilize the evolutionary dynamics of a generic disease model. Through the addition of $\ell_1$ and $\ell_2$ regularization terms to the objective function, we achieved the desired feedback structure. In future work, we plan to explore a principled integration of our methods with recent results on the robust $L_1$ stability of positive systems [25]. In particular, we hope to explicitly account for model error introduced due to model linearization, parametric uncertainty and unmodeled dynamics due to drug interactions.

VI. ACKNOWLEDGEMENTS

We would like to thank David Baltimore and Pamela Bjorkman for discussions regarding using antibody therapy for HIV treatment, and research scientist Anthony West for information on antibody neutralization parameters. We would like to thank Nikolai Matni for the review of the technical content. A. Rantzer gratefully acknowledges support of the LCCC Linnaeus Center and the eLLIIT Excellence Center at Lund University.

REFERENCES

### Fig. 4. Stabilizing gains found for nominal stabilizing controller, a robust controller using (8) that minimizes the $H_\infty$ closed loop norm and a robust controller using (6) that minimizes the $L_1$ norm of the closed loop system for evolutionary dynamics systems of the first eighteen HIV point mutants listed in Figure 5.

<table>
<thead>
<tr>
<th>Antibody associated escape mutants</th>
<th>Mutation</th>
<th>3BC176 IC50 µg/ml</th>
<th>PG16 IC50 µg/ml</th>
<th>45-46G54W IC50 µg/ml</th>
<th>PGT128 IC50 µg/ml</th>
<th>10-1074 IC50 µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td></td>
<td>0.319</td>
<td>0.512</td>
<td>0.024</td>
<td>0.169</td>
<td>0.312</td>
</tr>
<tr>
<td>3BC176</td>
<td>G471R</td>
<td>0.159</td>
<td>0.154</td>
<td>0.008</td>
<td>0.02</td>
<td>0.091</td>
</tr>
<tr>
<td>PG16</td>
<td>N160K</td>
<td>0.145</td>
<td>50</td>
<td>0.007</td>
<td>0.086</td>
<td>0.155</td>
</tr>
<tr>
<td></td>
<td>T162N</td>
<td>0.154</td>
<td>50</td>
<td>0.013</td>
<td>0.166</td>
<td>0.175</td>
</tr>
<tr>
<td>45-46G54W</td>
<td>N279I</td>
<td>0.209</td>
<td>0.294</td>
<td>50</td>
<td>0.064</td>
<td>0.177</td>
</tr>
<tr>
<td></td>
<td>N280Y</td>
<td>0.276</td>
<td>0.145</td>
<td>50</td>
<td>0.031</td>
<td>0.126</td>
</tr>
<tr>
<td>PGT128 or 10-1074</td>
<td>N332K</td>
<td>0.232</td>
<td>0.988</td>
<td>0.017</td>
<td>50</td>
<td>0.076</td>
</tr>
<tr>
<td></td>
<td>N332Y</td>
<td>0.269</td>
<td>0.632</td>
<td>0.01</td>
<td>50</td>
<td>13.596</td>
</tr>
<tr>
<td></td>
<td>S334N</td>
<td>0.218</td>
<td>0.615</td>
<td>0.02</td>
<td>50</td>
<td>7.308</td>
</tr>
<tr>
<td>Passenger mutations</td>
<td>Y61H</td>
<td>0.243</td>
<td>0.285</td>
<td>0.015</td>
<td>0.098</td>
<td>0.26</td>
</tr>
<tr>
<td></td>
<td>E102K</td>
<td>0.173</td>
<td>0.341</td>
<td>0.023</td>
<td>0.11</td>
<td>0.207</td>
</tr>
<tr>
<td></td>
<td>N295S</td>
<td>0.347</td>
<td>0.5</td>
<td>0.017</td>
<td>0.145</td>
<td>0.159</td>
</tr>
<tr>
<td></td>
<td>I311M</td>
<td>0.23</td>
<td>2.67</td>
<td>0.013</td>
<td>0.248</td>
<td>0.253</td>
</tr>
<tr>
<td></td>
<td>S365L</td>
<td>0.26</td>
<td>0.273</td>
<td>0.009</td>
<td>0.045</td>
<td>0.153</td>
</tr>
<tr>
<td></td>
<td>G366E</td>
<td>0.187</td>
<td>0.167</td>
<td>0.001</td>
<td>0.021</td>
<td>0.074</td>
</tr>
<tr>
<td></td>
<td>I371M</td>
<td>0.2</td>
<td>0.303</td>
<td>0.013</td>
<td>0.064</td>
<td>0.164</td>
</tr>
<tr>
<td></td>
<td>N413K</td>
<td>0.188</td>
<td>0.557</td>
<td>0.014</td>
<td>0.032</td>
<td>0.109</td>
</tr>
<tr>
<td></td>
<td>E429K</td>
<td>0.146</td>
<td>0.503</td>
<td>0.017</td>
<td>0.082</td>
<td>0.167</td>
</tr>
<tr>
<td></td>
<td>N295S-G366E-N413K</td>
<td>0.222</td>
<td>0.131</td>
<td>0.001</td>
<td>0.012</td>
<td>0.021</td>
</tr>
<tr>
<td>tri-mix</td>
<td>T162I-G458D</td>
<td>0.275</td>
<td>50</td>
<td>14.33</td>
<td>0.012</td>
<td>0.047</td>
</tr>
<tr>
<td></td>
<td>T162N-N280Y</td>
<td>0.138</td>
<td>50</td>
<td>50</td>
<td>0.027</td>
<td>0.079</td>
</tr>
<tr>
<td>penta-mix</td>
<td>N160K-N280Y-N332K</td>
<td>0.146</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>N160K-A281T-N332K</td>
<td>0.1</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>T162I-N280Y-N332K</td>
<td>0.13</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>T162I-N279K-N332K</td>
<td>0.149</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Signature + Passenger</td>
<td>T162I-Y61H</td>
<td>0.156</td>
<td>50</td>
<td>0.014</td>
<td>0.088</td>
<td>0.115</td>
</tr>
<tr>
<td></td>
<td>T162N-V430E</td>
<td>0.167</td>
<td>50</td>
<td>0.003</td>
<td>0.037</td>
<td>0.106</td>
</tr>
<tr>
<td></td>
<td>N280Y-A174T</td>
<td>0.064</td>
<td>0.138</td>
<td>50</td>
<td>0.01</td>
<td>0.021</td>
</tr>
<tr>
<td></td>
<td>N332S-N413K</td>
<td>0.181</td>
<td>0.526</td>
<td>0.017</td>
<td>50</td>
<td>0.05</td>
</tr>
<tr>
<td>Estimated Mutations</td>
<td>N160K-N280Y</td>
<td>0.276</td>
<td>50</td>
<td>50</td>
<td>0.086</td>
<td>0.155</td>
</tr>
<tr>
<td></td>
<td>N160K-N332K</td>
<td>0.232</td>
<td>50</td>
<td>0.017</td>
<td>50</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>N280Y-N332K</td>
<td>0.276</td>
<td>0.988</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>N295S-G366E</td>
<td>0.347</td>
<td>0.5</td>
<td>0.017</td>
<td>0.145</td>
<td>0.159</td>
</tr>
<tr>
<td></td>
<td>N295S-N413K</td>
<td>0.347</td>
<td>0.557</td>
<td>0.017</td>
<td>0.145</td>
<td>0.159</td>
</tr>
<tr>
<td></td>
<td>G366E-N413K</td>
<td>0.188</td>
<td>0.557</td>
<td>0.014</td>
<td>0.082</td>
<td>0.167</td>
</tr>
</tbody>
</table>

Fig. 5. IC50 values for the indicated antibodies on YU2 mutant viruses found in continuous antibody mono therapy experiments conducted by the Nussenzweig lab at Rockefeller University [9]. The trimix of antibodies is : 3BC176,PG16,45-46G54W, the penta-mix is 3BC176, PG16, 45-46G54W, PGT128 and 10-1074. Estimated two point mutations represent intermediary mutations needed for our model but not included in experimental results in [9]. The IC50 values were taken to be the maximum IC50 of both mutations.


